CFGS
HTGM

Concourse Financial Group Securities’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Concourse Financial Group Securities’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-28
Closed -$1.63K – 2389
2020
Q3 		$2K Hold
28
– – ﹤0.01% 2046
2020
Q2 		$4K Hold
28
– – ﹤0.01% 1787
2020
Q1 		$2K Buy
+28
New +$2.74K ﹤0.01% 1966

Other funds holding HTGM

CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Concourse Financial Group Securities's HTGM Position: Q4 2020 in Review

Concourse Financial Group Securities sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2020, closing a stake of 28 shares — an estimated $1.63K sold.

Concourse Financial Group Securities first reported a position in HTGM in Q1 2020 and held it in 3 quarters. The position peaked at $4K in Q2 2020. 23 funds tracked by Wall St. Rank hold HTGM as of Q4 2020.

  • Concourse Financial Group Securities reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Concourse Financial Group Securities sold 28 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2020, an estimated $1.63K.
  • Concourse Financial Group Securities first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
  • Concourse Financial Group Securities's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $4K in Q2 2020.
  • 23 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2020.

Based on Concourse Financial Group Securities's 13F filing for Q4 2020, filed 2 Feb 2021.